News

The Autonomic Disorders Special Interest Section is dedicated to exploring the intricate relationship between autonomic disorders and headache medicine. 

The mission of the AHS Complementary and Integrative Medicine (CIM) Special Interest Section is to raise more awareness about evidence-based therapies that can complement standard, medical therapies and help treat the whole person.

The Vestibular Migraine and Other Migraine Variants is a new Special Interest Section of the American Headache Society.

The Refractory Headache Special Interest Section (SIS) of the American Headache Society is dedicated to empowering clinicians in the accurate diagnosis and effective treatment of refractory headache disorders.

The American Headache Society’s Methodology, Design & Statistical Issues Section is a group of headache investigators dedicated to developing and disseminating research methods to conduct rigorous headache science.

This fall, the American Headache Society is proud to offer two programs dedicated to developing leaders within the Society and field of Headache Medicine. These professional development programs were designed to support AHS members at different stages in their careers.

The mission of the New Investigators and Trainees (NIT) Section of the American Headache Society is fourfold: to recruit and longitudinally support junior members as they embark into the exciting field of headache medicine, to create a forum for collaboration and mentorship/sponsorship...

For Pride Month, we would like highlight our LGBTQIA+ Health Special Interest Section, which is composed of a diverse group of professionals dedicated to advancing the clinical care for sexual and gender minorities who suffer from headache disorders. We are working on improving access to care and advocating for patients who identify as LGBTQIA+.

The AHS Diversity, Equity, and Inclusion (DEI) Task Force is an initiative commissioned in 2020 by then-President Dr. Peter Goadsby and the AHS Board of Directors. Our mission is to infuse DEI to enhance the leadership and membership of the AHS to provide equitable care and improve the lives of people with headache disorders.

The American Headache Society’s Behavioral Section is a group of clinicians and researchers committed to improving symptoms and quality of life among individuals with headache disorders through behavioral intervention. In addition to involvement in research supporting the efficacy of these interventions, we aim to improve behavioral health access through educating providers and patients.

The American Headache Society (AHS) and National Institute of Neurological Disorders and Stroke (NINDS) request your input during the Headache Research Priorities Public Comment Period.

The Underserved Populations in Headache Medicine Section is always striving to find ways to optimize management and treatment of headache disorders in our underserved communities.

The Women’s Health Special Interest Section is a diverse group of professionals that aim to advance women’s health in headache medicine

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.